FDA-Approved HIV Medications

The Latest

This Week in HIV Research: Exorcizing Our PrEP Demons

Experts push for normalization of PrEP; U.S. HIV transmission rates across the care continuum; sociodemographic disadvantage and HIV drug resistance; real-world success of integrase inhibitors for treatment-experienced people.

By Myles Helfand

Dual Maintenance Therapy With Dolutegravir + Rilpivirine

In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.

By Sean R. Hosein for Canadian AIDS Treatment Information Exchange

Why HIV Care Providers Should Discuss Marijuana Use With Their Patients

What are the benefits and risks of marijuana use for people living with HIV? The answer is complicated, and explains why clinician-patient communication on the issue is increasingly important.

By Sony Salzman

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

By Barbara Jungwirth

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

By Barbara Jungwirth and Myles Helfand

Efavirenz Side Effects and Other Drug-Drug Interactions Are Common in Ugandan Cohort

Drug-drug interactions and side effects, associated with currently-used first-line antiretroviral therapy, are under-reported and managed in Uganda.

By Polly Clayden for HIV i-Base

China Approves Albuvirtide: A Once-Weekly Injectable Entry Inhibitor

On June 6, 2018, without news from the U.S. FDA, a press release from Frontier Biotech announced the approval of a new HIV drug in China that is given by once-weekly injection.

By Simon Collins for HIV i-Base

This Week in HIV Research: Monday, Wednesday, Treatment Days

Happy days for thrice-weekly dosing; shortfalls in chronic opioid therapy monitoring; neurocognition, treatment initiation, and high CD4; the link between influenza virus shedding and CD4 count.

By Barbara Jungwirth and Myles Helfand

The Evolution of Antiretroviral Therapy: Past, Present, and Future

The detection, diagnosis, and treatment of HIV has evolved rapidly. This review summarizes the past, present, and future of antiretrovirals for the treatment and prevention of HIV.

By Milena Mclaughlin, Pharm.D, M.S.C., BCPS-AQ ID, AAHIVP, and Jason Schafer, Pharm.D., M.P.H., BCPS, AAHIVP for American Academy of HIV Medicine

Efavirenz Might Decrease Effectiveness of the Vaginal Contraceptive Ring

Efavirenz (Sustiva, Stocrin) alters hormone exposure from the vaginal ring in HIV positive women, similar or greater to that previously reported with oral hormonal contraceptives.

By Polly Clayden for HIV i-Base